2,635 results match your criteria Cancer Discov[Journal]


Early Data Supports Avapritinib for Gastrointestinal Stromal Tumors.

Authors:

Cancer Discov 2020 Jul 10. Epub 2020 Jul 10.

The TKI avapritinib showed preliminary evidence of efficacy in gastrointestinal stromal tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-RW2020-104DOI Listing

Berzosertib Is Safe, with Signs of Efficacy against Advanced Solid Tumors.

Authors:

Cancer Discov 2020 Jul 10. Epub 2020 Jul 10.

The ATR inhibitor berzosertib produced responses with or without the DNA-damaging agent carboplatin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-RW2020-103DOI Listing

The CD70 Antibody Cusatuzumab Shows Promise in Acute Myeloid Leukemia.

Authors:

Cancer Discov 2020 Jul 10. Epub 2020 Jul 10.

Cusatuzumab synergized with a hypomethylating agent in older patients with acute myeloid leukemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-RW2020-106DOI Listing

Immune-Checkpoint Blockade Induces Colitis via Immune-Cell Alterations.

Authors:

Cancer Discov 2020 Jul 10. Epub 2020 Jul 10.

Immune-checkpoint blockade (ICB) changed immune-cell populations and gene expression in the colon. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-RW2020-105DOI Listing

The Disabled homolog 2 controls pro-metastatic activity of tumor-associated macrophages.

Cancer Discov 2020 Jul 10. Epub 2020 Jul 10.

Department of Medicine, Section of Immunology, University of Verona

Tumor-associated macrophages (TAMs) are regulators of extracellular matrix (ECM) remodeling and metastatic progression, the main cause of cancer-associated death. We found that disabled 2 mitogen-responsive phosphoprotein (DAB2) is highly expressed in tumor-infiltrating TAMs and its genetic ablation significantly impairs lung metastasis formation. DAB2-expressing TAMs, mainly localized along the tumor invasive front, participate in integrin recycling, ECM remodeling and directional migration in a tridimensional matrix. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-20-0036DOI Listing

Viral Analysis: Early Detection of HCC.

Authors:

Cancer Discov 2020 Jul 9. Epub 2020 Jul 9.

A recent study suggests that a method that identifies exposure to viral infections could allow earlier diagnosis of hepatocellular carcinoma (HCC). The method discriminated patients with HCC from at-risk and healthy people and determined that at-risk individuals developed HCC almost 9 years earlier than it could be detected with standard screening techniques. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-NB2020-065DOI Listing

Extracellular ATP and CD39 activate cAMP-mediated mitochondrial stress response to promote cytarabine resistance in acute myeloid leukemia.

Cancer Discov 2020 Jul 8. Epub 2020 Jul 8.

Centre de Recherche en Cancerologie de Toulouse, Inserm and Universite de Toulouse

Relapses driven by chemoresistant leukemic cell populations are the main cause of mortality for patients with acute myeloid leukemia (AML). Here, we show that the ectonucleotidase CD39 (ENTPD1) is upregulated in cytarabine (AraC)-resistant leukemic cells from both AML cell lines and patient samples in vivo and in vitro. CD39 cell surface expression and activity is increased in AML patients upon chemotherapy compared to diagnosis and enrichment in CD39-expressing blasts is a marker of adverse prognosis in the clinics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-19-1008DOI Listing
July 2020
15.929 Impact Factor

New Method Enables Design of Protein Drugs That Covalently Bind Targets.

Authors:

Cancer Discov 2020 Jul 6. Epub 2020 Jul 6.

Modified PD-1 incorporating an unnatural amino acid covalently bound PD-L1 to shrink tumors . Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-RW2020-099DOI Listing

Genomic Lesions Unrepaired at Mitosis Affect Clonal Evolution in Cancer.

Authors:

Cancer Discov 2020 Jul 6. Epub 2020 Jul 6.

Mutagen-induced DNA lesions were not all resolved prior to mitosis, yielding mutational strand bias. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-RW2020-102DOI Listing

Dendritic-Cell PD-L1 Mediates CD8 T Cell-Dependent Antitumor Immunity.

Authors:

Cancer Discov 2020 Jul 6. Epub 2020 Jul 6.

Deficiency of dendritic cell-expressed PD-L1 reduced tumor growth and increased T-cell infiltration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-RW2020-100DOI Listing

Modified IL18 Overcomes a Barrier to IL18-Based Immunotherapy Efficacy.

Authors:

Cancer Discov 2020 Jul 6. Epub 2020 Jul 6.

IL18 engineered not to bind a decoy receptor, but not normal IL18, had antitumor efficacy in mice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-RW2020-101DOI Listing

Toward a New Molecular Taxonomy of Diffuse Large B-cell Lymphoma.

Cancer Discov 2020 Jul 2. Epub 2020 Jul 2.

British Columbia Cancer Centre for Lymphoid Cancer, Vancouver, British Columbia, Canada.

Diffuse large B-cell lymphoma (DLBCL) represents a grouping of clinically and biologically heterogeneous tumors. Application of advanced molecular technology has significantly expanded our knowledge of DLBCL pathobiology, allowing identification of subgroups with common, potentially targetable, biological themes. Here, we review the recent molecular analyses that could provide a paradigm shift to a new taxonomy, foundational to the rational transition to precision medicine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-20-0174DOI Listing

Disparities Persist in Cancer Careers.

Authors:

Cancer Discov 2020 Jul 2. Epub 2020 Jul 2.

Minority scientists-especially Black scientists-have long been underrepresented in the oncology workforce, likely due to a low number of minority students starting and continuing careers in science and medicine. Although progress has been made through government programs that offer students of all ages opportunities to explore careers in oncology, more work is needed to promote diversity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-ND2020-012DOI Listing

It Takes a Village to Overcome KRAS Dependence in Pancreatic Cancer.

Cancer Discov 2020 Jul;10(7):910-912

Schulze Center for Novel Therapeutics, Division of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, Minnesota.

In this issue, Hou and colleagues present their exciting work demonstrating that, through remodeling of the local tumor microenvironment (TME), pancreatic ductal adenocarcinoma forms a tumor-supportive niche capable of liberating cancer cells from dependence on oncogenic KRAS signaling. Through extensive experimentation both and , the authors reveal that the HDAC5-CCL2 axis drives the recruitment of tumor-associated macrophages to the TME to provide trophic signaling.. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-20-0490DOI Listing

Utility of Human-Derived Models for Glioblastoma.

Cancer Discov 2020 Jul;10(7):907-909

Departments of Neurology, Pediatrics, Neurological Surgery, Brain Tumor Research Center, and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.

In this issue, Pine and colleagues compared single-cell RNA-sequencing data across four distinct types of glioblastoma stem cell-derived tumor models, reinforcing the importance of a three-dimensional microenvironment for accurate recapitulation of cellular states.. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-20-0493DOI Listing

Fusing the Genetic Landscape of Infantile High-Grade Gliomas.

Cancer Discov 2020 Jul;10(7):904-906

Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington.

In this issue of , Clarke and colleagues define the genetic landscape of infantile cerebral high-grade gliomas, which frequently contain alterations in the MAPK pathway, as well as recurrent gene fusions in receptor tyrosine kinases () and neurotrophic receptor kinases (). Combining their multi-omic profiling data with functional preclinical and clinical studies, this large multi-institutional study provides strong rationale for future classification and molecular subtype-specific therapeutic management of infantile high-grade glioma.. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-20-0495DOI Listing

Poly(ADP-ribose) glycohydrolase inhibition sequesters NAD+ to potentiate the metabolic lethality of alkylating chemotherapy in IDH mutant tumor cells.

Cancer Discov 2020 Jun 30. Epub 2020 Jun 30.

Department of Neurosurgery, Massachusetts General Hospital / Harvard Medical School

Nicotinamide adenine dinucleotide (NAD+) is an essential cofactor metabolite and is the currency of metabolic transactions critical for cell survival. Depending on tissue context and genotype, cancer cells have unique dependencies on NAD+ metabolic pathways. Poly(ADP-ribose) polymerases (PARPs) catalyze oligomerization of NAD+ monomers into poly(ADP-ribose) (PAR) chains during cellular response to alkylating chemotherapeutics, including procarbazine or temozolomide. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-20-0226DOI Listing

Leukemia cell of origin influences apoptotic priming and sensitivity to LSD1 inhibition.

Cancer Discov 2020 Jun 30. Epub 2020 Jun 30.

Department of Pediatric Oncology, Dana-Farber Cancer Institute

The cell of origin of oncogenic transformation is a determinant of therapeutic sensitivity, but the mechanisms governing cell-of-origin-driven differences in therapeutic response have not been delineated. Leukemias initiating in hematopoietic stem cells (HSC) are less sensitive to chemotherapy and highly express the transcription factor Evi1 compared to leukemias derived from myeloid progenitors. Here, we compared leukemias initiated in either HSCs or myeloid progenitors to reveal a novel function for Evi1 in modulating p53 protein abundance and activity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-19-1469DOI Listing

The IDH1 Inhibitor Ivosidenib May Slow -Mutant Glioma Progression.

Authors:

Cancer Discov 2020 Jun 26. Epub 2020 Jun 26.

Ivosidenib, an inhibitor of mutant IDH1, was safe and showed early evidence of efficacy in glioma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-RW2020-095DOI Listing

Senolytic CAR T Cells Targeting uPAR Treat Lung Cancer in Mice.

Authors:

Cancer Discov 2020 Jun 26. Epub 2020 Jun 26.

In mice, senescence-targeted CAR T cells extended survival in lung cancer and improved liver fibrosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-RW2020-098DOI Listing

Berzosertib May Synergize with Gemcitabine in Serous Ovarian Cancer.

Authors:

Cancer Discov 2020 Jun 26. Epub 2020 Jun 26.

Berzosertib upped survival in those with platinum-resistant tumors and short platinum-free intervals. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-RW2020-097DOI Listing

Partitioning into Phase-Separated Condensates Mediates Drug Activity.

Authors:

Cancer Discov 2020 Jun 26. Epub 2020 Jun 26.

Anticancer drugs' ability to concentrate in condensates containing their targets affected activity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-RW2020-096DOI Listing

Tiragolumab Impresses in Multiple Trials.

Authors:

Cancer Discov 2020 Jun 23. Epub 2020 Jun 23.

The TIGIT inhibitor tiragolumab, alone or in combination with the PD-L1 inhibitor atezolizumab, may be effective against solid cancers. In phase I and II trials, the agent achieved statistically significant results in multiple solid malignancies-most notably non-small cell lung cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-NB2020-063DOI Listing

Personalized Vaccine Induces Antitumor Activity.

Authors:

Cancer Discov 2020 Jun 23. Epub 2020 Jun 23.

A personalized cancer vaccine, when combined with the PD-L1 inhibitor atezolizumab, has shown early promise in patients with solid cancers: In a phase Ib trial, the therapy induced neoantigen-specific T-cell responses-and elicited complete or partial tumor eradication in some patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-NB2020-064DOI Listing

Limited Environmental Serine and Glycine Confer Brain Metastasis Sensitivity to PHGDH Inhibition.

Cancer Discov 2020 Jun 22. Epub 2020 Jun 22.

Radiation Oncology, New York University Langone Medical Center

A hallmark of metastasis is the adaptation of tumor cells to new environments. Metabolic constraints imposed by the serine and glycine-limited brain environment restrict metastatic tumor growth. How brain metastases overcome these growth-prohibitive conditions is poorly understood. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-19-1228DOI Listing
June 2020
15.929 Impact Factor

Targeting CD19-CD22 Aids Younger Patients with ALL.

Authors:

Cancer Discov 2020 Jun 22. Epub 2020 Jun 22.

In a phase I trial of chimeric antigen receptor T cells targeting CD19 and CD22 in younger patients with relapsed or refractory B-cell acute lymphoblastic leukemia, toxicity was manageable, and five of 12 patients had complete responses. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-NB2020-060DOI Listing

Dendritic Cells Form Synapses to Transfer Tumor Antigens to Each Other.

Authors:

Cancer Discov 2020 Jun 19. Epub 2020 Jun 19.

Tumor antigen-loaded vesicles were transferred between dendritic cells for presentation to T cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-RW2020-093DOI Listing

Diffuse Large B-cell Lymphoma Responds to Tafasitamab plus Lenalidomide.

Authors:

Cancer Discov 2020 Jun 19. Epub 2020 Jun 19.

Patients with relapsed or refractory diffuse large B-cell lymphoma responded to a novel combination. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-RW2020-091DOI Listing

Neutrophil Extracellular Traps Attract Metastatic Cells to New Sites.

Authors:

Cancer Discov 2020 Jun 19. Epub 2020 Jun 19.

DNA-protein complexes called neutrophil extracellular traps were chemoattractants for metastatic cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-RW2020-094DOI Listing

Liquid Biopsy Method Identifies Cancer Invasiveness and Metastasis.

Authors:

Cancer Discov 2020 Jun 19. Epub 2020 Jun 19.

A liquid biopsy-based method, dubbed EV-CLUE, discerned breast cancer invasiveness and metastasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-RW2020-092DOI Listing

Tumors Appear Rife with Bacterial Lodgers.

Authors:

Cancer Discov 2020 Jun 18. Epub 2020 Jun 18.

Intracellular bacteria are widespread in tumors throughout the body, forming distinct populations that may play a critical role in shaping the microenvironment of cancers, according to a comprehensive survey of more than 1,000 tumor microbiomes across seven cancer types. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-NB2020-062DOI Listing

Epigenetic switch-induced viral mimicry evasion in chemotherapy resistant breast cancer.

Cancer Discov 2020 Jun 16. Epub 2020 Jun 16.

Medical Biophysics, University of Toronto, Princess Margaret Cancer Center-University Health Network, Ontario Institute for Cancer Research

Tumor progression upon treatment arises from pre-existing resistant and/or adaptation of persister cancer cells committing to an expansion phase. Here, we show that evasion from viral mimicry response allows the growth of taxane-resistant triple-negative breast cancer (TNBC). This is enabled by an epigenetic state adapted to taxane-induced metabolic stress, where DNA hypomethylation over loci enriched in transposable elements (TEs) is compensated by large chromatin domains of H3K27me3 to warrant TE repression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-19-1493DOI Listing

Lineage reversion drives WNT independence in intestinal cancer.

Cancer Discov 2020 Jun 16. Epub 2020 Jun 16.

Medicine, Weill Cornell Medicine

The WNT pathway is a fundamental regulator of intestinal homeostasis and hyperactivation of WNT signaling is the major oncogenic driver in colorectal cancer (CRC). To date, there are no described mechanisms that bypass WNT dependence in intestinal tumors. Here, we show that while WNT suppression blocks tumor growth in most organoid and in vivo CRC models, the accumulation of CRC-associated genetic alterations enables drug resistance and WNT-independent growth. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-19-1536DOI Listing

AMG 510 Shows Activity beyond NSCLC.

Authors:

Cancer Discov 2020 Jun 15. Epub 2020 Jun 15.

The latest results from the CodeBreak 100 trial evaluating AMG 510 indicate that this first-in-class KRAS inhibitor, having shown promise in non-small cell lung cancer, is modestly active in several other types of solid tumors, including colorectal cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-NB2020-061DOI Listing

T Cells Targeting MAGE-A4 Shrink Tumors.

Authors:

Cancer Discov 2020 Jun 15. Epub 2020 Jun 15.

Autologous T cells engineered to target the MAGE-A4 cancer testis antigen successfully shrank a wide range of solid tumors with a manageable toxicity profile. In a phase I trial, the therapy, ADP-A2M4, showed the most promise in synovial sarcoma, yielding a disease control rate of around 90%. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-NB2020-059DOI Listing

Phase I trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 and non-BRCA1/2 mutant cancers.

Cancer Discov 2020 Jun 12. Epub 2020 Jun 12.

Institute of Cancer Research.

Preclinical studies have demonstrated synergy between poly(ADP-ribose) polymerase (PARP) and phosphatidylinositol-3-kinase (PI3K)/AKT pathway inhibitors in BRCA1 and BRCA2 (BRCA1/2)-deficient and BRCA1/2-proficient tumors. We conducted an investigator-initiated phase I trial utilizing a prospective intrapatient dose-escalation design to assess two schedules of capivasertib (AKT inhibitor) with olaparib (PARP inhibitor) in 64 patients with advanced solid tumors. Dose expansions enrolled germline BRCA1/2-mutant tumors, or BRCA1/2-wildtype cancers harboring somatic DNA damage response (DDR) or PI3K/AKT pathway alterations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-20-0163DOI Listing

Targeting Dysregulation in Cancer.

Cancer Discov 2020 Jul 12;10(7):922-934. Epub 2020 Jun 12.

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.

Aberrant MET signaling can drive tumorigenesis in several cancer types through a variety of molecular mechanisms including gene amplification, mutation, rearrangement, and overexpression. Improvements in biomarker discovery and testing have more recently enabled the selection of patients with MET-dependent cancers for treatment with potent, specific, and novel MET-targeting therapies. We review the known oncologic processes that activate MET, discuss therapeutic strategies for MET-dependent malignancies, and highlight emerging challenges in acquired drug resistance in these cancers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-19-1446DOI Listing

Histone Methylation Connects DNA Repair to Metabolism in Cancer Cells.

Authors:

Cancer Discov 2020 Jun 12. Epub 2020 Jun 12.

Metabolites produced in cancer cells interfered with resolution of DNA double-strand breaks. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-RW2020-089DOI Listing

Resistance-Linked Stress-Induced Mutagenesis Is MTOR-Mediated in Cancer.

Authors:

Cancer Discov 2020 Jun 12. Epub 2020 Jun 12.

MTOR was a critical node modulating stress-induced mutagenesis (SIM) in cancer and . Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-RW2020-090DOI Listing

Tucatinib Is Active Against Brain Metastases in HER2 Breast Cancer.

Authors:

Cancer Discov 2020 Jun 12. Epub 2020 Jun 12.

The small-molecule tyrosine kinase inhibitor tucatinib outperformed placebo against brain metastases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-RW2020-087DOI Listing

Contact with Cancer Cells Induces Inflammatory Pathways in Fibroblasts.

Authors:

Cancer Discov 2020 Jun 12. Epub 2020 Jun 12.

Transcytosis from cancer cells into fibroblasts triggered the cGAS-STING pathway. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-RW2020-088DOI Listing

Drug Designs Take Aim at OX40 Stimulation.

Authors:

Cancer Discov 2020 Jun 10. Epub 2020 Jun 10.

Following the failure of several OX40 agonist antibody candidates, findings from an early-stage trial suggest a way forward to activate the costimulatory receptor. In the trial, intratumoral injections of mRNA encoding the OX40 ligand yielded favorable immunologic and molecular effects in patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-NB2020-058DOI Listing

COVID-19 Delays Cancer Screenings.

Authors:

Cancer Discov 2020 Jun 8. Epub 2020 Jun 8.

In recent months, the COVID-19 pandemic has caused many institutions to pause routine cancer screenings-delays that may not be problematic for patients but can create challenges for healthcare providers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-NB2020-055DOI Listing

RBMS1 suppresses colon cancer metastasis through targeted stabilization of its mRNA regulon.

Cancer Discov 2020 Jun 8. Epub 2020 Jun 8.

Biochemistry & Biophysics, Helen Diller Family Comprehensive Cancer Center, University of California - San Francisco School of Medicine

Identifying master regulators that drive pathological gene expression is a key challenge in precision oncology. Here, we have developed an analytical framework, named PRADA, that identifies oncogenic RNA-binding proteins through the systematic detection of coordinated changes in their target regulons. Application of this approach to data collected from clinical samples, patient-derived xenografts, and cell line models of colon cancer metastasis revealed the RNA-binding protein RBMS1 as a suppressor of colon cancer progression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-19-1375DOI Listing

The INPP4B Tumor Suppressor Modulates EGFR Trafficking and Promotes Triple Negative Breast Cancer.

Cancer Discov 2020 Jun 8. Epub 2020 Jun 8.

Department of Pathology, and Cancer Center, Beth Israel Deaconess Medical Center, Beth Israel Deaconess Medical Center

Inactivation of the tumor suppressor lipid phosphatase INPP4B is common in triple negative breast cancer (TNBC). We generated a genetically-engineered TNBC mouse model deficient in INPP4B. We found a dose-dependent increase in tumor incidence in INPP4B homozygous and heterozygous knockout mice compared to wild-type, supporting a role for INPP4B as a tumor suppressor in TNBC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-19-1262DOI Listing

Proof-of-Concept with PROTACs in Prostate Cancer.

Authors:

Cancer Discov 2020 Jun 5. Epub 2020 Jun 5.

Preliminary clinical data for ARV-110, a proteolysis-targeting chimera that flags the androgen receptor for degradation, indicate that the drug is safe and shows some efficacy in men with metastatic castration-resistant prostate cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-NB2020-054DOI Listing

Ileal Apoptosis and Microbiota Mediate Colon Cancer Treatment Efficacy.

Authors:

Cancer Discov 2020 Jun 5. Epub 2020 Jun 5.

Oxaliplatin caused ileal apoptosis and T-cell enrichment and perturbed microbiota in colon cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-RW2020-084DOI Listing

Hypoxia-Induced Epigenetic Dysregulation Promotes Infantile Ependymoma.

Authors:

Cancer Discov 2020 Jun 5. Epub 2020 Jun 5.

Posterior fossa A (PFA) ependymomas required a hypoxic environment to maintain their epigenomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-RW2020-083DOI Listing

Cancer Markedly and Dynamically Alters the Systemic Immune System.

Authors:

Cancer Discov 2020 Jun 5. Epub 2020 Jun 5.

Cancer perturbed the systemic immune system in mice, with strong dependence on tumor type and size. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-RW2020-086DOI Listing